Abstract:Tumor immunotherapy is a novel strategy for cancers,which has great significance and applicationprospects in clinical treatment.It mainly includes adoptive cell therapy,tumor vaccines and monoclonal antibodytherapy.Antibodies are widely used in tumor immunotherapy,but their price is too high,the quality is easilyinfluenced by different batches and have immunogenicity.Aptamers,also known as"chemical antibodies",areshort single-stranded oligonucleotides which bind to their targets with high specificity and affinity.Aptamerswhich have low immunogenicity,are synthesized at low cost and quality stability.Based on these advantages,aptamers have been developed for tumor immunotherapy in recent years which mainly includes two aspects.Oneis to select immune-related aptamers,and the other is to expand the application of aptamers that have beenreported to tumor immunotherapy.Using immune checkpoints,co-stimulatory receptors or cytokines as targets,the aptamers can be obtained through screening.However,it is uncertain whether the aptamer has the biologicalfunction of regulating the anti-tumor immune response.Therefore,the process of screening should be improvedby adding appropriate screening pressure to obtain functional aptamers that can regulate antitumor immuneresponse.There are many aptamers which have been reported,but rarely have been investigated for furtherresearch and application.So we can further develop these aptamers for tumor immunotherapy.For example,aptamers can be coupled with siRNA or nanomaterials to indirectly regulate tumor immune processes.Themodification of membrane of immune cells with aptamers confers the immune cells targeted tumor-killing effects.Aptamers play an important role in tumor immunotherapy in a variety of ways,and have great potential to bedeveloped for clinical treatment.We need to improve the aptamer screening process to obtain aptamers that havepowerful biological functions quickly and maximize the use of the aptamers that have been obtained

Anti-idiotype Antibody Vaccines in Tumour Immunotherapy:Current Situation and Future Promises

The Past, Present and Future of Immunotherapy Against Tumor.

Anti-angiogenic Active Immunotherapy: a New Approach to Cancer Treatment

Advances in Tumor Antigen‐Based Anticancer Immunotherapy: Recent Progress, Prevailing Challenges, and Future Perspective

Development of tumour peptide vaccines: From universalization to personalization

Recent advances of neoantigen in tumor therapy

Recent Advances in Cancer Immunotherapy

Study of anti-idiotype vaccine against ovarian carcinoma

Emerging immunological strategies: recent advances and future directions

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects

Antigen Self-Presenting Nanovaccine for Cancer Immunotherapy.

Research Progress of Aptamer-mediated Tumor Immunotherapy

Cancer Vaccines: Promising Therapeutics or an Unattainable Dream

Overview of Mimotopes and Related Strategies in Tumor Vaccine Development.

Peptide‐based therapeutic cancer vaccine: Current trends in clinical application

Cancer immunotherapies: advances and bottlenecks.

Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy

Therapeutic cancer vaccines: advancements, challenges, and prospects

Neoantigen: A New Breakthrough in Tumor Immunotherapy

Cancer Vaccines As Promising Immuno-Therapeutics: Platforms and Current Progress

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects